Demonstrated on-mechanism, single agent anti-tumor activity in heavily pre-treated patients with transcriptionally addicted solid tumors Showed manageable safety profile, with no grade 3/4 neutropenia, dose

KRON

Is Apple Holding Back On Vision Pro Storage Variants? Mark Gurman Thinks So

By Sudhanshu Singh

January 10, 5:23 AM

Gurman, in a series of tweets on Thursday, voiced his uncertainty about the existence of multiple storage capacities for the Vision Pro.

AAPL

Tiziana Life Sciences Reports 3-Month Neuroimaging Scores In Multiple Sclerosis Patients Receiving Intranasal Foralumab; A Primary Endpoint With Clinical Measures Of EDSS (Disability) And MFIS (Fatigue) Is Currently Underway

By Benzinga Newsdesk

April 25, 10:01 AM

Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced for the first time,

TLSA

Guggenheim Downgrades Generac Hldgs to Neutral

Related Posts

Shark Tank’s Kevin O’Leary Slams Crypto Exchanges For Suing Regulators: ‘Stupid Idea’

Kronos Bio Presents Preliminary Data From Phase 1 Dose Escalation Portion Of Phase 1/2 KB-0742 Study At AACR-NCI-EORTC

Is Apple Holding Back On Vision Pro Storage Variants? Mark Gurman Thinks So

Tiziana Life Sciences Reports 3-Month Neuroimaging Scores In Multiple Sclerosis Patients Receiving Intranasal Foralumab; A Primary Endpoint With Clinical Measures Of EDSS (Disability) And MFIS (Fatigue) Is Currently Underway